Literature DB >> 9878769

Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels.

M S Smith1, U B Schambra, K H Wilson, S O Page, D A Schwinn.   

Abstract

alpha1-Adrenergic receptors (alpha1ARs) are important in lower urinary tract syndromes such as benign prostatic hypertrophy and bladder irritability. Spinal cord alpha1ARs have been postulated to play a role in modulating these diseases, yet alpha1AR subtype (alpha1a, alpha1b, alpha1d) neuronal localization in human spinal cord has not been described. We therefore tested the hypothesis that alpha1AR subtype distribution varies according to specific spinal cord tract and level. In situ hybridization was performed to identify cell bodies containing alpha1AR subtype mRNA at four levels of human spinal cord (cervical enlargement, thoracic, lumbar, sacral). alpha1AR mRNA is present in ventral gray matter only (ventral>dorsal; sacral>lumbar=thoracic>cervical). Signaling cell bodies were detected in anterior horn motor neurons at all levels; dorsal nucleus of Clarke and intermediolateral columns in cervical enlargement, thoracic and lumbar spinal cord regions; and parasympathetic nucleus in sacral spinal cord. Although all three alpha1AR subtypes are present throughout human spinal cord, alpha1d mRNA predominates overall. If confirmed at a protein level, these findings may contribute to the development of new therapeutic strategies in the treatment of several human diseases. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9878769     DOI: 10.1016/s0169-328x(98)00287-3

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  29 in total

Review 1.  CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.

Authors:  Karl-Erik Andersson; Rikard Pehrson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 3.  Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.

Authors:  Debra A Schwinn; Claus G Roehrborn
Journal:  Int J Urol       Date:  2008-03       Impact factor: 3.369

4.  Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2009

Review 5.  Combination pharmacological therapies for the management of benign prostatic hyperplasia.

Authors:  Seth A Cohen; J Kellogg Parsons
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 6.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

7.  α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume.

Authors:  Osamu Yokoyama; Yoshitaka Aoki; Akira Tsujimura; Tetsuya Takao; Mikio Namiki; Akihiko Okuyama
Journal:  World J Urol       Date:  2010-04-13       Impact factor: 4.226

Review 8.  Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction.

Authors:  Michael R Ruggieri; Alan S Braverman; Michel A Pontari
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

9.  Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?

Authors:  Cees Korstanje; Walter Krauwinkel; Francisca L C van Doesum-Wolters
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

10.  Selective α1A-blocker improves bladder storage function in rats via suppression of C-fiber afferent activity.

Authors:  Osamu Yokoyama; Hideaki Ito; Yoshitaka Aoki; Nobuyuki Oyama; Yoshiji Miwa; Hironobu Akino
Journal:  World J Urol       Date:  2009-10-16       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.